Sihuan Pharmaceutical Holdings Group Ltd (0460) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Sihuan Pharmaceutical Holdings Group Ltd stock HK$0.53, price HK$0.78, that is 32.1% below the price, quality 57 out of 100. Rating: overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.
How to read this chart
60‑month range HK$0.4724 – HK$2.66 · fair‑value band HK$0.4900 – HK$0.7100 · the HK$0.7800 price screens above the HK$0.5300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.
Follow Sihuan Pharmaceutical Holdings Group in your weekly email
Every Wednesday you see whether Sihuan Pharmaceutical Holdings Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China, the United States, and internationally.
Show moreShow less
It operates in three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine.
The company offers filling, shaping, supporting, supplementing, optoelectronic devices, body sculpturing, skin care, and other services, as well as non- or minimally invasive comprehensive medical aesthetics solutions.
It also provides drugs for cardio-cerebral vascular, digestive system, anti-infective, metabolism, respiratory, neurology, oncology, diabetes, and other indications, as well as modern Chinese medicine and industrial hemp products. In addition, the company offers general hospital services.
Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong.
Stock analysis
Sihuan Pharmaceutical Holdings Group Ltd (0460) currently trades at HK$0.7800, while our model-based Fair Value estimate is HK$0.5300, 32% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of HK$1.18 per share, and 6 of the 17 models we run sit above the HK$0.7800 price.
Bear case: the Asset-Based group reads lowest at HK$0.1100, and 11 of the 17 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$0.4900 (bear) to HK$0.7100 (bull), the price of HK$0.7800 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Sihuan Pharmaceutical Holdings Group Ltd reported revenue of 2.6B CNY in FY2025 versus 3.0B CNY in FY2021, a compound −3.7%/yr. Reported net income was 180M CNY in FY2025, compounding −19.0%/yr from FY2021.
Key figures
Market cap HK$7.0B (≈ $898M) Small · P/E ratio 18.3 · P/S ratio 1.25 · Dividend yield 1.4% · Net margin 6.9% · Return on equity 5.6% · Return on assets (EBIT) −0.9% (5-year average) · Operating margin 19.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −32%, 0460 screens richer than that median.
Fair Value models
BearHK$0.4900Fair Value HK$0.5300BullHK$0.7100
Price HK$0.7800 · Downside -32.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+37.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.2%
Start year 2020 (pandemic). Over 10 years: −1.9% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−14.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−16.0%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−16.0% vs −19.3%, picking up
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 23%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 3.9%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Sihuan Pharmaceutical Holdings Group Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−32.1% · Below median
Profitability
Return on equity (12 months)5.6% · Below median
Return on assets1.5% · Below median
Net margin (12 months)11.5% · Above median
Operating margin (12 months)19.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)1.3% · Below median
Dividend yield (12 months)1.4% · Below median
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)18.3× · Cheaper than median
P/B1.02× · Cheapest 25%
P/S (12 months)2.28× · Cheaper than median
EV/EBITDA4.8× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 18
FUTURE (revenue growth)7· sector 25
PAST (return on equity)22· sector 25
HEALTH (low debt)94· sector 96
DIVIDEND (yield)28· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sihuan Pharmaceutical Holdings Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/0460
Frequently asked questions
Is Sihuan Pharmaceutical Holdings Group Ltd (0460) overvalued or undervalued?
As of Nov 13, 2026, our model estimates a fair value of HK$0.5300 versus a price of HK$0.7800, about 32% lower (overvalued).
What is the fair value of 0460?
Our model-based fair value for Sihuan Pharmaceutical Holdings Group Ltd is HK$0.5300 (as of Nov 13, 2026), built from audited fundamentals. The current price: HK$0.7800.
What is the quality score of 0460?
Sihuan Pharmaceutical Holdings Group Ltd has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sihuan Pharmaceutical Holdings Group Ltd (0460)?
Our model-based price target is the fair value of HK$0.5300 (as of Nov 13, 2026) from 17 valuation models. Cautious scenario HK$0.4900, optimistic scenario HK$0.7100. It is a calculation from audited fundamentals, not an analyst target.
What is the Sihuan Pharmaceutical Holdings Group Ltd stock forecast for 2026?
Our models put fair value at HK$0.5300, about 32% lower versus a price of HK$0.7800 (overvalued). Cautious scenario HK$0.4900, optimistic scenario HK$0.7100. The calculation is refreshed regularly with new filings.
What is the revenue of Sihuan Pharmaceutical Holdings Group Ltd (0460)?
Sihuan Pharmaceutical Holdings Group Ltd reported trailing-twelve-month revenue of about 2.6B CNY (latest available figure, as of Nov 13, 2026).
Does Sihuan Pharmaceutical Holdings Group Ltd pay a dividend?
Sihuan Pharmaceutical Holdings Group Ltd currently shows a dividend yield of 1.40% relative to its recent price (as of Nov 13, 2026).
How much is the dividend of Sihuan Pharmaceutical Holdings Group Ltd (0460) and when is the ex-dividend date?
Sihuan Pharmaceutical Holdings Group Ltd pays a dividend of HK$0.0109 per share a year, a dividend yield of 1.4%. The last ex-dividend date was Jun 30, 2026. A dividend has been paid every year since at least 2011. The payout ratio is 47.0% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Sihuan Pharmaceutical Holdings Group Ltd (0460)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sihuan Pharmaceutical Holdings Group Ltd it is HK$0.5300 per share (as of Nov 13, 2026), against a price of HK$0.7800. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Sihuan Pharmaceutical Holdings Group Ltd stock overvalued or undervalued in 2026?
As of Nov 13, 2026, 0460 trades above its calculated fair value: price HK$0.7800, fair value HK$0.5300, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0460?
No. The price is what the market pays today (HK$0.7800); the fair value is what the company's own numbers justify (HK$0.5300). For Sihuan Pharmaceutical Holdings Group Ltd the two are HK$0.2500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sihuan Pharmaceutical Holdings Group Ltd worth?
The market values Sihuan Pharmaceutical Holdings Group Ltd at about HK$7.0B (market capitalisation, as of Nov 13, 2026). Per share that is HK$0.7800; our models calculate a fair value of HK$0.5300 per share.
What do the bullish and bearish scenarios say about 0460?
Our models span a range for Sihuan Pharmaceutical Holdings Group Ltd: cautious scenario HK$0.4900, base HK$0.5300, optimistic HK$0.7100 per share (as of Nov 13, 2026, price HK$0.7800). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0460?
Sihuan Pharmaceutical Holdings Group Ltd trades at a price-to-earnings ratio of 18.3 (as of Nov 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.5300 is built from several models across several years. Other multiples: P/B 1.0, P/S 2.3, EV/EBITDA 4.8.
How solid is the balance sheet of Sihuan Pharmaceutical Holdings Group Ltd (0460)?
Balance-sheet figures for Sihuan Pharmaceutical Holdings Group Ltd (as of Nov 13, 2026): return on equity 5.6%, debt of 0.12 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 0460 from its 52-week high?
Sihuan Pharmaceutical Holdings Group Ltd trades at HK$0.7800, about 54% below its 52-week high of HK$1.68 and 12% above the low of HK$0.6950 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.5300 is for.
Which stocks are comparable to Sihuan Pharmaceutical Holdings Group Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sihuan Pharmaceutical Holdings Group Ltd stock attractive at the current price?
The data as of Nov 13, 2026: price HK$0.7800, calculated fair value HK$0.5300 (−32%), Quality Score 57/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0460 calculated?
We run Sihuan Pharmaceutical Holdings Group Ltd through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$0.5300 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. Sihuan Pharmaceutical Holdings Group Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sihuan Pharmaceutical Holdings Group Ltd (0460)?
The closing price on Nov 13, 2026 was HK$0.7800. Our model-based fair value is HK$0.5300, about 32% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sihuan Pharmaceutical Holdings Group Ltd right now?
The price sits above even our optimistic bull case (HK$0.7100). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Sihuan Pharmaceutical Holdings Group Ltd
How large is the market capitalisation of Sihuan Pharmaceutical Holdings Group Ltd (0460)?
The market capitalisation of Sihuan Pharmaceutical Holdings Group Ltd is HK$7.0B (≈ $898M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sihuan Pharmaceutical Holdings Group Ltd (0460)?
The price-to-sales ratio of Sihuan Pharmaceutical Holdings Group Ltd is 1.25 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Sihuan Pharmaceutical Holdings Group Ltd (0460)?
The dividend yield of Sihuan Pharmaceutical Holdings Group Ltd is 1.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sihuan Pharmaceutical Holdings Group Ltd (0460)?
The net margin of Sihuan Pharmaceutical Holdings Group Ltd is 6.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sihuan Pharmaceutical Holdings Group Ltd (0460)?
The return on equity (ROE) of Sihuan Pharmaceutical Holdings Group Ltd is 5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sihuan Pharmaceutical Holdings Group Ltd (0460)?
On an EBIT basis the return on assets of Sihuan Pharmaceutical Holdings Group Ltd is −0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sihuan Pharmaceutical Holdings Group Ltd (0460)?
The operating margin of Sihuan Pharmaceutical Holdings Group Ltd is 19.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sihuan Pharmaceutical Holdings Group Ltd (0460)?
Revenue at Sihuan Pharmaceutical Holdings Group Ltd is growing +1.3% versus a year earlier (3y avg +6.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sihuan Pharmaceutical Holdings Group Ltd (0460)?
Earnings per share at Sihuan Pharmaceutical Holdings Group Ltd are growing +124% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sihuan Pharmaceutical Holdings Group Ltd (0460) generate?
The free cash flow of Sihuan Pharmaceutical Holdings Group Ltd is −218M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sihuan Pharmaceutical Holdings Group Ltd (0460) hold?
Sihuan Pharmaceutical Holdings Group Ltd holds more cash than debt, 2.6B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sihuan Pharmaceutical Holdings Group Ltd in the live analysis
One click puts Sihuan Pharmaceutical Holdings Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 13, 2026